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Abbreviations 
AJCC    American Joint Committee on Cancer 
CT    Computed Tomography 
DSS    Disease Specific Survival  
IRAS   Integrated Research Application System 
MRI    Magnetic Resonance Imaging 
NS   Not significant 
OS    Overall Survival  
PET CT   Positron Emission Tomography ComputedTomography 
PFS    Progression Free Survival PFS 
SD   Standard Deviation 
SLNB    Sentinel lymph node biopsy  
Tc99m   Technetium 99 
WLE   Wide Local excision 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
Introduction: Sentinel lymph node biopsy (SLNB) in cutaneous melanoma (CM) is 
performed to identify patient at risk of regional and distant relapse. We hypothesized 
that timing of lymphoscintigraphy may influence the accuracy of SLNB and patient 
outcomes.  
 
Methods: We reviewed prospective data on patients undergoing SLNB for CM at a 
large university cancer-center between 2008-2015, examining patient and tumor 
demographics and time between lymphoscintigraphy (LS) and SLNB. Kaplan-Meier 
survival analysis assessed disease-specific (DSS) and overall-survival (OS), stratified 
by timing of LS. Cox multivariate regression analysis assessed independent risk 
factors for survival.  
 
Results: We identified 1015 patients. Median follow-up was 45 months (IQR 26-68 
months). Univariate analysis showed a 6.8% absolute DSS (HR 1.6 [1.03-2.48], p= 
0.04) benefit and a 10.7% absolute OS (HR 1.64 [1.13-2.38], p=0.01) benefit for 
patients whose SLNB was performed < 12 hrs of LS (n= 363) compared to those 
performed >12 hours (n=652). Multivariate analysis identified timing of LS as an 
independent predictor of OS (p=0.007) and DSS (p=0.016) when competing with age, 
sex, Breslow thickness (BT) and SLN status. No difference in nodal relapse rates 
(5.2% v 4.6%; p=0.67) was seen. Both groups were matched for age, sex, BT and 
SLN status. 
 
Conclusion: These data have significant implications for SLNB services, suggesting 
delaying SLNB >12 hours after LS using a Tc99-labelled nanocolloid has a 
significant negative survival impact for patients and should be avoided. We 
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hypothesise that temporal tracer migration is the underlying cause and advocate 
further trials investigating alternative, 'stable' tracer-agents. 
 
 
 
 
 
Introduction 
Sentinel lymph node biopsy (SLNB) was established by Morton et al. 1 as a means of 
accurately locating and staging lymphatic fields draining a specific melanoma 
primary tumor site in patients with clinical stage I and II disease. This technique has 
evolved from surgical wide local excision and elective lymphadenectomy 2 in all 
patients  to selective combined multidisciplinary-delivered pre-operative nodal basin 
identification by lymphoscintigraphy, and intra-operative dual-localization using 
radio-labelled tracers 3 and blue dye to specifically isolate the nodes for removal and 
histopathological staging, thereby reducing surgical morbidity in 80% of patients who 
would  otherwise not develop regional nodal disease4.  
In keeping with this, radio-tracers have been developed with the goal of creating a 
stable, specific colloid that is taken up and retained by antigen-presenting cells within 
a lymph node without the potential to migrate proximally to higher second echelon 
nodes 5. Technetium-99m labelled nanocolloid is the preferred agent in our unit, with 
lymphoscintigraphy undertaken on same day, or day before surgery, and early and 
delayed images taken to ensure accuracy of nodal identification and exclusion of 
higher echelon nodes.  Studies by Kalady and Oldan  et al 6,7 using Tc 99 labeled 
sulphur-colloid and blue dye demonstrated accurate sentinel node identification 
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without missing metastatic disease in patients injected up to 24 hours prior to 
surgery6.  We observed a small but significant number of patients who presented 
during follow up with nodal or distant melanoma metastasis following negative 
SLNB. We hypothesized that timing of lymphoscintigraphy was potentially causing a 
negative impact on patients, and undertook a retrospective review of our prospective 
melanoma database, examining outcomes of all patients with melanoma post SLNB.  
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Methods 
Patients 
Patients with AJCC clinical stage I-IIC primary melanoma 8 were prospectively 
selected for SLNB following review of primary histology and radiological imaging 
results by the specialist multidisciplinary skin cancer team at a University Hospital 
tertiary referral center in East Anglia, United Kingdom. A retrospective review of 
prospectively collected computerized patient data from September 2009 until 
December 2015, specifically examining patients with a histologically confirmed 
diagnosis of melanoma was undertaken. 
 
Sentinel Node Localization and Identification 
Standardized intradermal injections of 20-40MBq Technetium 99 labelled 
nanocolloid (GE Healthcare, Milan, Italy) to the primary tumor site was performed in 
Nuclear Medicine, followed by early dynamic imaging at ten minutes and delayed 
planar imaging at sixty minutes to localize the sentinel node on the preceding day, or 
day of surgery.  Surgery was performed by one of two authors (MDM and MJH).  
Intra-operatively, patent bleu (Guebert) injections to the primary tumor bed were 
undertaken and the sentinel node was identified by dual-localization, with intra-
operative hand-held gamma probe to confirm accuracy of node removal via radiation 
counts >10% of the primary site and objective visualization of blue staining of the 
node and its afferent lymphatic channels. Incision time was recorded in addition to 
time taken to identification of node. Nodes were preserved in formalin and examined 
histologically using haematoxylin and eosin and with immunostaining for S100, 
Melan-A and HMB-45.  
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Follow up and identification of disease recurrence 
Patients with a negative SLNB and no residual disease on wide local excision were 
followed up in a dedicated skin cancer clinic at three and six-monthly intervals.  
Patients with high risk melanoma (defined by Breslow thickness >4mm or SLN 
positivity) were offered whole body CT scans at 6 monthly intervals. Metastatic 
disease was investigated on basis of clinical history and examination, with ultrasound-
guided biopsy used to histologically confirm nodal disease and cross-sectional 
imaging including MRI brain and whole-body PET-CT to identify distant metastatic 
disease. Histological confirmation was obtained where feasible to confirm disease-
specific recurrence.  
 
 Statistical analysis 
Statistical analysis using GraphPad Prism 7.0 included Chi squared tests to compare 
variables, Cox multivariate regression analysis to examine independent factors for 
outcomes, and Kaplan-Meier survival curves to review nodal recurrence, progression 
free survival (PFS), disease specific survival (DSS) and overall survival (OS).  
 
Ethical approval  
Ethical & HRA approval was obtained (IRAS Ref: 234471) for undertaking a 
retrospective review of prospectively gathered data from the melanoma database.  
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Results 
Patient characteristics 
 1015 patients were identified for inclusion in the study. Demographic data and tumor 
characteristics are shown in Table 1.   Mean age was 52 years (range: 18-86) and median 
Breslow thickness was 2.33mm (range: 0.5mm-24mm). The primary site was not recorded in 
4 cases and ulceration status was missing in 45 cases. The overall sentinel node positivity rate 
was 17.0% (173 patients). Median follow up was 45 months (IQR 26-68 months). Groups 
were analysed according to early (<12 hours from lymphoscintigraphy to SLNB) versus late 
(>12 hours) lymphoscintigraphy. There was no significant difference between the cohorts in 
age, gender, Breslow thickness and sentinel node status.  
 
Sentinel node identification 
We observed an increased tendency towards late lymphoscintigraphy to SLNB in the second 
half of the study time- period. Dividing the study into two cohorts (one treated 2008-2011 
and the other 2012-2015) showed a decrease in early lymphoscintigraphy rate from 40.8% to 
31.6% (p=0.002 Chi squared test, Figure 1). Lymphoscintograms were reported by a 
radiologist on the same day, and nodal basin site and numbers of sentinel nodes or second 
echelon nodes information available to the operating surgeon.  Lymphoscintigraphy failed to 
localize a sentinel node basin in two patients pre-operatively. Histology of tissue removed at 
surgery demonstrated fibrofatty tissue only. Neither of the patients had recurrence of disease 
in the follow up period of the study.  The average number of lymph nodes identified at 
lymphoscintigraphy was 1.99, compared to numbers removed at surgery 2.36 (p<0.0001).  
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Length of time between lymphoscintigraphy and SLNB influences survival outcomes 
Survival analysis was performed, stratifying by timing of Tc99m nanocolloid injections and 
lymphoscintigraphy to time of SLNB. We divided it into 6, 9, 12 and 18 hours from surgery. 
We observed a significant difference in overall survival (OS) and disease-specific survival 
(DSS), with a cut-off at 12 hours (Figure 2A+B). Univariate analysis demonstrated a 10.7% 
OS benefit at 96 months (Hazard ratio 1.64 [1.13-2.38], p=0.010) (Figure 2A) and a DSS 
benefit of 6.8% at 96 months (Figure 2B, Hazard ratio 1.60 [1.03-2.48], p=0.035) for patients 
who underwent lymphoscintigraphy less than 12 hours prior to SLNB compared to those who 
underwent it more than 12 hours afterwards. There was no significant difference between 
nodal relapse rates (p=0.67) as shown in Figure 2C or progression-free survival (p=0.16, data 
not shown). Subgroup analysis was performed to compare optimal timing of 
lymphoscintigraphy, dividing groups into patients undergoing lymphoscintigraphy <6 hours, 
<9 hours, <12 hours and >18 hours prior to SLNB. This showed a clear dichotomy in OS 
with threshold at patients treated under versus over 12 hours, p< 0.003 (Figure 3).  
 
Lymphoscintigraphy timing is an independent predictor of OS and DSS 
 Cox Multivariate analysis confirmed timing of lymphoscintigraphy as an independent 
predictor of OS (p<0.007) and DSS (p<0.016) when competing with age, sex, Breslow 
thickness and sentinel node status. This data is shown in Table 4. Female gender, age and 
tumor-free sentinel node all demonstrated improved overall DSS and OS. 
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Discussion 
 
Running a sentinel node service requires multidisciplinary coordination between nuclear 
medicine, the operating team and histopathology department. According to our local 
protocol, patients routinely spend up to 120 minutes undergoing early and delayed imaging in 
nuclear medicine prior to surgery. With access to nuclear medicine facilities limited to day-
time working hours and performing of surgery on planned elective lists, undertaking 
lymphoscintigraphy the day prior to surgery confers several economic advantages, 
specifically coordination of pre-operative planning, dedicated SLNB operating sessions and 
having single operator performing the surgery, maintaining efficiency and consistency of the 
service. Other groups have investigated feasibility of delayed SLNB between 18-24 hours 
after injections in both breast 9,10  and melanoma 6,7,11,12 patients, and have reported this is a 
safe and acceptable means for node identification; with delayed SLNB resulting in reduction 
in background radioactivity and enhancing accuracy in node detection. Moreover, repeat 
imaging did not demonstrate migration of tracer to higher echelon nodes. None of the patients 
in the studies developed nodal recurrence, and concordance with blue dye of 69% was 
reported 11 On this basis, our unit policy has been to perform SLNB up to 24 hours after 
radio-tracer injections and lymphoscintigraphy, without repeating planar imaging on the day 
of surgery in the late group. We observed in our study that at surgery significantly more 
lymph nodes were removed compared to the numbers of nodes identified on imaging 
(p<0.0001), hence making the possibility of inadequate sampling of lymph nodes less likely.  
 
There was a slight change in rate of early versus late sentinel node biopsies post radio-tracer 
injection over the study time frame. There was a higher proportion of patients undergoing 
delayed lymphoscintigraphy in the second cohort of the study. It is unlikely therefore that this 
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in itself has introduced a bias as it is likely that survival is improved in the second half of the 
study period. 
 
 
Technetium 99m- Nanocolloid is eliminated primarily by the kidneys, and to a lesser extent 
by gastrointestinal tract, and hasin vivo half-life of 32 hours, with particle size between 3-
16nm 13.  From the findings of our study, we postulate, that the radio-tracer may have 
migrated more proximally to higher echelon nodes, hence remaining detectable at time of 
surgery using the gamma probe however not necessarily representing the true sentinel node.  
We were unable to directly examine the concordance of the blue dye staining of the sentinel 
node with the nanocolloid, which is a potential limitation of this study. Other groups 14 have 
reported that accuracy of blue dye alone in sentinel node identification is between 52-95%, 
while use of dye with radio-tracer allows node localization rates of 98-99%.  In terms of 
identification of tumor positive nodes, radio-tracers have reported accuracy of 100% 15 
compared to 80% by blue dye. Hu et al 16report that blue dye does not improve tumor 
detection in SLNB and is not retained by the lymph nodes unlike the colloids.  
 
Age was determined to be an independent risk factor in predicting DSS (p< 0.0048) and OS 
(p<0.001). Studies by Conway et al 17 and Chao et al 18  demonstrated that lymphatic function 
declined with age, potentially due to changes in the dermis, alteration in tissue turgor and 
changes in lymph nodes with fatty infiltration,  with significant reduction in count rates with 
age >60. Use of concurrent blue dye at time of surgery did not affect the gamma counts in 
this patient population, reducing risk of volumes injected influencing the sentinel node uptake 
of tracers. 
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Nodal relapse rate between patients undergoing early versus late SLNB did not differ at 
follow up, with recurrence occurring in 19 patients (5.5%) in the early group (n=344) and 30 
patients (4.8%) of late group (n=622, p=0.16 ns). Our findings concur with other studies 
examining false negative rates for SLNB, which have been reported as between 6-21%  19 . 
MSLT 1  20 demonstrated removal of the sentinel node prolonged DSS for all patients with 
cutaneous melanoma, and in patients with AJCC stage 3 disease prolonged distant metastatic 
disease melanoma-specific survival. We observed in our patient population, that patients 
undergoing early SLNB following lymphoscintigraphy had improved overall and DSS 
compared to patients undergoing late SLNB, suggesting that in itself, removal of the sentinel 
node has an impact on overall prognosis.  
 
Other groups 21 have reported that late recurrences tend to arise from melanomas on distal 
sites (i.e limbs), however in our study population, we did not observe any difference in terms 
of primary disease location and late recurrences, as seen in Table 1 our samples were evenly 
matched in terms of anatomical site distribution, so this is unlikely to account for the 
difference in survival.   
 
 
New advances in radio-tracers have led to development of cell-receptor specific 
radiopharmaceutical. Tilmanocept is a Tc99m labelled radio-tracer with specific affinity for 
CD206 receptors expressed on antigen-presenting cells. Phase III trials demonstrated it to 
have high concordance in sentinel node identification in both melanoma and breast cancer 
patients when compared with blue dye 15,22.  In a recent trial of its use in SLNB for head and 
neck cancer, 6% of the study cohort (n=5) patients with cutaneous SCC were included and 
none were demonstrated to have nodal metastasis following SLNB and elective neck 
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dissection. 23,24 Advances in development of targeted receptor-specific radio-tracer could lead 
to improvements in accuracy of SLNB in patients with cutaneous melanoma.  
 
International differences exist between radio-tracers used for the pre-operative identification 
of the SLN. In the United States micro-filtered Tc99 labelled Sulfur colloid is used with the 
majority of the particles measuring 0.2 microns or greater in diameter. In comparison, 
European centers use Tc99m nanocolloid (particle size <0.08 microns) and Australian centers 
employ Tc99m antimony tri-sulfide (particle size 0.003-0.03 microns)25-27 thus particle sizes 
of the colloid particles routinely used in the US are significantly larger.  Colloid migration to 
the nodal basin is determined by both lymphatic flow and particle size 28 Our study is based 
on the use of nanocolloid as a primary radio-tracer, other large studies examining feasibility 
of delayed lymphoscintigraphy were based on Tc99m Sulfur colloid. We suggest that the 
order of magnitude difference in particle sizes in the colloids between the studies is the major 
underlying reason for the discrepancy in the findings with regards to patient outcomes in 
delayed lymphoscintigraphy, whereby the difference in survival is produced by temporal 
migration of the tracer agent from the sentinel node to the non-sentinel node, resulting in a 
sampling error, with the incorrect node being harvested at SLNB. A proportion of these will 
be positive meaning they will be allowed to propagate metastases undetected, therefore 
negatively impacting on survival.  
 
This current study is limited to data from a single center, therefore validation of data from 
other sites may help to improve our understanding of the observations made from our patient 
group.  
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Conclusion 
To the best of our knowledge, this is the largest series to examine DSS and OS in melanoma 
patients undergoing early and delayed SLNB following Tc99 nanocolloid radio-tracer 
injections. We believe our data may have significant implications for SLNB services using 
this tracer agent. It suggests that delaying SLNB beyond 12 hours after lymphoscintigraphy 
using a Tc99-labelled nanocolloid has a significant and large negative survival impact for 
patients and should be avoided. We hypothesise that temporal tracer migration is the 
underlying cause and we advocate further trials investigating alternative, ‘stable’ tracer 
agents. 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
15 
 
Acknowledgements 
 
The authors gratefully acknowledge the assistance of Beverley Underwood Clinical Nurse 
Specialist in the prospective maintenance of the Melanoma Database. 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
16 
 
References 
 
 
1. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic 
mapping for early stage melanoma. Arch Surg. Apr 1992;127(4):392-399. 
2. Neuhaus SJ, Clark MA, Thomas JM. Dr. Herbert Lumley Snow, MD, MRCS (1847-
1930): the original champion of elective lymph node dissection in melanoma. Ann 
Surg Oncol. Sep 2004;11(9):875-878. 
3. Bedrosian I, Scheff AM, Mick R, et al. 99mTc-human serum albumin: an effective 
radiotracer for identifying sentinel lymph nodes in melanoma. J Nucl Med. Jul 
1999;40(7):1143-1148. 
4. Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH. Improved long-term 
survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis 
of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg. 
Oct 1991;214(4):491-499; discussion 499-501. 
5. Bennett LR, Lago G. Cutaneous lymphoscintigraphy in malignant melanoma. 
Seminars in Nuclear Medicine. 1983;13(1):61-69. 
6. Kalady MF, White DC, Fields RC, et al. Validation of delayed sentinel lymph node 
mapping for melanoma. Cancer J. Nov-Dec 2001;7(6):503-508. 
7. Oldan JD, James OG, Mosca PJ, Tyler DS, Borges-Neto S. Two-day 
lymphoscintigraphic imaging for melanoma. Nucl Med Commun. Aug 
2014;35(8):870-875. 
8. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma 
staging and classification. J Clin Oncol. Dec 20 2009;27(36):6199-6206. 
9. Wang HY, Tsai CC, Hung GU, Lin WY. Effectiveness of delayed 2-day 
lymphoscintigraphy on sentinel lymph node detection in patients with breast cancer 
with negative early lymphoscintigraphy. Clin Nucl Med. Sep 2006;31(9):523-526. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
17 
 
10. Wang H, Heck K, Pruitt SK, et al. Impact of delayed lymphoscintigraphy for sentinel 
lymphnode biopsy for breast cancer. J Surg Oncol. Jun 2015;111(8):931-934. 
11. White DC, Schuler FR, Pruitt SK, et al. Timing of sentinel lymph node mapping after 
lymphoscintigraphy. Surgery. Aug 1999;126(2):156-161. 
12. Rodgaard JC, Kramer S, Stolle LB. Sentinel node biopsy (SNB) in malignant 
melanoma as same day procedure vs delayed procedure: clinical and economic 
outcome. J Plast Surg Hand Surg. Aug 2014;48(4):265-269. 
13. Jimenez IR, Roca M, Vega E, et al. Particle sizes of colloids to be used in sentinel 
lymph node radiolocalization. Nucl Med Commun. Feb 2008;29(2):166-172. 
14. Ariyan S, Ariyan C, Farber LR, Fischer DS, Flynn SD, Truini C. Reliability of 
identification of 655 sentinel lymph nodes in 263 consecutive patients with malignant 
melanoma. J Am Coll Surg. Jun 2004;198(6):924-932. 
15. Sondak VK, King DW, Zager JS, et al. Combined analysis of phase III trials 
evaluating [(9)(9)mTc]tilmanocept and vital blue dye for identification of sentinel 
lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol. Feb 
2013;20(2):680-688. 
16. Hu Y, Melmer PD, Slingluff CL, Jr. Localization of the Sentinel Lymph Node in 
Melanoma Without Blue Dye. Ann Surg. Mar 2016;263(3):588-592. 
17. Conway WC, Faries MB, Nicholl MB, et al. Age-related lymphatic dysfunction in 
melanoma patients. Ann Surg Oncol. Jun 2009;16(6):1548-1552. 
18. Chao C, Martin RC, 2nd, Ross MI, et al. Correlation between prognostic factors and 
increasing age in melanoma. Ann Surg Oncol. Mar 2004;11(3):259-264. 
19. Sondak VK, Zager JS. Who is to blame for false-negative sentinel node biopsies in 
melanoma? Ann Surg Oncol. Mar 2010;17(3):670-673. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
18 
 
20. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node 
biopsy versus nodal observation in melanoma. N Engl J Med. Feb 13 
2014;370(7):599-609. 
21.   Murali, R. Desilva, C. Thompson, J. F. Scolyer, R. A. et al.,   Factors predicting         
recurrence and survival in sentinel lymph node-positive melanoma patients. Ann Surg,   
2011.   253(6): p. 1155-64. 
22. Wallace AM, Han LK, Povoski SP, et al. Comparative evaluation of 
[(99m)tc]tilmanocept for sentinel lymph node mapping in breast cancer patients: 
results of two phase 3 trials. Ann Surg Oncol. Aug 2013;20(8):2590-2599. 
23. Agrawal A, Civantos FJ, Brumund KT, et al. [(99m)Tc]Tilmanocept Accurately 
Detects Sentinel Lymph Nodes and Predicts Node Pathology Status in Patients with 
Oral Squamous Cell Carcinoma of the Head and Neck: Results of a Phase III Multi-
institutional Trial. Ann Surg Oncol. Oct 2015;22(11):3708-3715. 
24. Marcinow AM, Hall N, Byrum E, Teknos TN, Old MO, Agrawal A. Use of a novel 
receptor-targeted (CD206) radiotracer, 99mTc-tilmanocept, and SPECT/CT for 
sentinel lymph node detection in oral cavity squamous cell carcinoma: initial 
institutional report in an ongoing phase 3 study. JAMA Otolaryngol Head Neck Surg. 
Sep 2013;139(9):895-902. 
25. Alazraki N, Glass EC, Castronovo F, Olmos RA, Podoloff D, Society of Nuclear M. 
Procedure guideline for lymphoscintigraphy and the use of intraoperative gamma 
probe for sentinel lymph node localization in melanoma of intermediate thickness 1.0. 
J Nucl Med. Oct 2002;43(10):1414-1418. 
26. Alazraki NP, Eshima D, Eshima LA, et al. Lymphoscintigraphy, the sentinel node 
concept, and the intraoperative gamma probe in melanoma, breast cancer, and other 
potential cancers. Semin Nucl Med. Jan 1997;27(1):55-67. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
19 
 
27. Eshima D, Eshima LA, Gotti NM, et al. Technetium-99m-sulfur colloid for 
lymphoscintigraphy: effects of preparation parameters. J Nucl Med. Sep 
1996;37(9):1575-1578. 
28. Moncayo VM, Aarsvold JN, Alazraki NP. Lymphoscintigraphy and sentinel nodes. J 
Nucl Med. Jun 2015;56(6):901-907. 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
20 
 
FIGURE LEGENDS 
 
Figure 1  
Comparison of distribution of timing of lymphoscintigraphy by year 
 Patients were divided into two cohorts (2008-2011 and 2012-2015) and the proportion of 
patients undergoing lymphoscintigraphy early (<12 hours) was compared with late (>12 
hours). The results show showed a decrease in early lymphoscintigraphy rate from 40.8% to 
31.6% in the second cohort (Chi squared test p=0.002) 
 
Figure 2 
Comparison of OS, DSS and nodal relapse rates in early versus late treatment groups 
2A Kaplan Meier survival curve, which shows that there is a reduction in OS of 10.6 % 
(p=0.01, HR 1.64 [1.13-2.38]) in patients undergoing SLNB > 12 hours post Tc-99m 
nanocolloid injections.  
2B Kaplan Meier survival curve, which shows a significant reduction (p=0.04) in DSS in 
patients undergoing SLNB > 12 hours post Tc-99m nanocolloid injections. 
 2C Kaplan Meier survival curve which does not show any significant difference (p=0.67) in 
nodal relapse rates between early versus late treatment groups 
 
Figure 3  
Comparison of OS in treatment groups according to time course 
OS is compared between groups patients undergoing Tc99m-nanocolloid injections 6,9, 12 
and 18 hours prior to sentinel lymph node biopsy using Kaplan Meier curves. The results 
show a significant difference (p<0.003) between patients undergoing early versus late 
lymphoscintigraphy, with the greatest difference observed at 12 hours 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
21 
 
Table 1 
Comparison of demographics and tumor characteristics between early (<12 hours) and late 
(>12 hours) post lymphoscintigraphy. There was no significant difference (ns) between 
groups for sex, age, tumor characteristics and sentinel node status 
Patient and Tumor 
Demographics 
EARLY (%) 
n=362 
LATE (%) 
n=653 p 
Male 176 (%) 345 (%) ns 
Female 186 (51.2%) 308 (47.2%)   
Age ± SD (years) 60.1 ± 13.6 60.6 ± 13.7   
Breslow thickness       
Median 1.8 1.7 ns 
Mean 2.44 ±2.18 2.32±1.88   
Tumor site       
Limb 162 (44.8%) 292 (44.7%) ns  
Trunk 141 (38.9%) 264 (40.4%)   
Head and neck 57 (15.8%) 95 (14.6%)   
Not recorded 2 (0.6%) 2 (0.3%)   
Ulceration       
Present 73 (20.2%) 168 (25.7%)   
Absent 268 (74%) 461 (70.6%)   
Unknown 21 (5.8%) 24 (3.7%)   
Sentinel node       
Negative 296 (81.8%) 546 (83.6%) ns 
Positive 66 (18.2%) 107 (16.4%)   
Nodal relapses       
Number 19 30 ns 
Incidences 5.25% 4.60%   
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Table 2: 
Cox Multivariate analysis of overall survival and disease specific survival examining 
independent risk factors. Each of timing of lymphoscintigraphy (early versus late), gender 
age, Breslow thickness and sentinel node status were independently associated with survival 
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